肿瘤细胞治疗研究
英文原题：Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.
Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.
头颈癌（HNC）是全球第六大常见癌症类型，约占所有癌症类型的4%。
头颈癌（HNC）是全球第六大常见癌症类型，约占所有癌症类型的4%。在所有HNC中，大多数为头颈部鳞状细胞癌（HNSCC），其临床治疗包括手术、放疗、化疗、免疫治疗、靶向治疗和多模式治疗。近年来，嵌合抗原受体（CAR）-T细胞免疫治疗显著改变了白血病和淋巴瘤的治疗方法，并作为多种癌症的潜在治疗手段受到越来越多的关注。然而，实体瘤中的CAR-T免疫治疗，尤其是HNSCC，由于缺乏肿瘤特异性抗原、高水平的肿瘤异质性、免疫抑制性肿瘤微环境、治疗相关毒性风险以及HNSCC中的脱靶不良事件而明显滞后。本综述的目的是探讨CAR-T细胞治疗在HNSCC治疗中的进展。我们旨在概述HNSCC中的靶抗原，突出挑战和潜在解决方案，并讨论相关的联合治疗。本综述全面概述了CAR-T细胞治疗HNSCC的最新进展，并为未来的研究方向提供了有价值的见解。
Head and neck cancer (HNC) ranks as the sixth most prevalent type of cancer globally and accounts for about 4% of all types of cancer. Among all HNC, most are head and neck squamous cell carcinoma (HNSCC) with clinical therapies that include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and multimodal treatments. In recent years, chimeric antigen receptor (CAR)-T cell immunotherapy has significantly transformed the therapeutic approaches for leukemia and lymphoma and has garnered increased attention as a potential treatment for a wide range of cancers. However, CAR-T immunotherapy in solid tumors, especially HNSCCs, lags significantly behind due to the paucity of tumor-specific antigens, high levels of tumor heterogeneity, immunosuppressive tumor microenvironment, the risk of treatment-related toxicities and off-target adverse events in HNSCCs. The objective of this review is to explore the advancement of CAR-T cell therapy in the treatment of HNSCCs. We aim to outline the targeted antigens in HNSCCs, highlight the challenges and potential solutions, and discuss the relevant combination therapies. Our review presents a comprehensive overview of the recent developments in CAR-T cell therapy for HNSCCs, and provides valuable insights into future research avenues.
MEMBER ACCOUNT
登录成功会直接打开下一页。
